TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19713967

Group type: EXPERIMENTAL
Intervention: Active HHQ-reduced coffee (300 mg chlorogenic acids per 184 ml of coffee)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo HHQ-reduced coffee (0 mg chlorogenic acids per 184 ml of coffee)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Active HHQ-reduced coffee
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo HHQ-reduced coffee
Number of subjects: 21
Study: 17597089

Group type: EXPERIMENTAL
Intervention: ECC rinse with unfractionated heparin (UFH)
Number of subjects: 10

Group type: COMPARATOR
Intervention: ECC rinse without unfractionated heparin (UFH)
Number of subjects: 10
Study: 15302734

Group type: EXPERIMENTAL
Intervention: Rhythm control strategy
Number of subjects: 205

Group type: COMPARATOR
Intervention: Rate control group
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Rhythm control group
Number of subjects: 205

Group type: COMPARATOR
Intervention: Composite end point (all-cause mortality, thromboembolic events, major bleeding)
Number of subjects: 205
Study: 11462953

Group type: EXPERIMENTAL
Intervention: Pouch and Roux-en-Y (PR; n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pouch and interposition (PI; n = 15)
Number of subjects: 30
Study: 9664650

Group type: EXPERIMENTAL
Intervention: Positive mood
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral mood
Number of subjects: 0
Study: 8002117

Group type: EXPERIMENTAL
Intervention: Fluid ingestion (F) - 400 ml bolus of 20 mmol/l NaCl immediately before exercise and 120 ml feedings every 10 min during the first 50 min of exercise.
Number of subjects: 6

Group type: COMPARATOR
Intervention: No fluid ingestion (NF) - no fluid ingested before or during exercise.
Number of subjects: 6
Study: 2527244

Group type: EXPERIMENTAL
Intervention: Epinephrine (EPI)
Number of subjects: 26

Group type: COMPARATOR
Intervention: No Epinephrine (no EPI)
Number of subjects: 26
Study: 776040

Group type: EXPERIMENTAL
Intervention: Butorphanol tartrate
Number of subjects: 127

Group type: COMPARATOR
Intervention: Morphine sulfate
Number of subjects: 127
Study: 30674610

Group type: EXPERIMENTAL
Intervention: Bifidobacterium abundance in early infancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum subspecies infantis
Number of subjects: 0
Study: 29212509

Group type: EXPERIMENTAL
Intervention: Low-dose, high-frequency (LDHF) training
Number of subjects: 40
Study: 25919644

Group type: EXPERIMENTAL
Intervention: Test formulation of finasteride (1.0 mg)
Number of subjects: 38
Study: 24298760

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) applied at Qugu (CV 2), Zhongji (CV 3), Shuidao (ST 28), Qihai (CV 6), Guanyuan (CV 4), 5 times a week
Number of subjects: 204

Group type: COMPARATOR
Intervention: Indwelling catheter applied at intervals of 2-4 hours with periodic bladder irrigation and rehabilitation training
Number of subjects: 204
Study: 16087660

Group type: EXPERIMENTAL
Intervention: Amino acid mixture (Vamin 18 g N/l)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Equicaloric glucose
Number of subjects: 6

Group type: COMPARATOR
Intervention: Ringer's acetate
Number of subjects: 6
Study: 12932063

Group type: EXPERIMENTAL
Intervention: Remifentanil/Propofol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Remifentanil/Isoflurane
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Remifentanil/Propofol and Remifentanil/Isoflurane
Number of subjects: 80
Study: 10491213

Group type: EXPERIMENTAL
Intervention: Bone specific alkaline phosphatase (BALP)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Osteocalcin (bone Gla protein, BGP)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Pyridinoline (Pyr)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Deoxypyridinoline (Dpyr)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Computed tomography (CT) measurements of cross-sectional areas of vertebrae and femurs
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Apparent density of cancellous bone in vertebrae
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Volume and material density of cortical bone in femurs
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: BALP and BGP
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Pyr and Dpyr
Number of subjects: 269
Study: 8700092

Group type: EXPERIMENTAL
Intervention: Gentle human touch (GHT) for 15 minutes a day from day 7 to day 12 of life
Number of subjects: 0
Study: 1725539

Group type: EXPERIMENTAL
Intervention: Diltiazem (sustained-release or conventional tablets)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Diltiazem and captopril (combination therapy)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Diltiazem with hydrochlorothiazide or atenolol (combination therapy)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Diltiazem (monotherapy)
Number of subjects: 15
Study: 6614298

Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sterile saline
Number of subjects: 10
Study: 31567875

Group type: EXPERIMENTAL
Intervention: Typical presentation format for Genitourinary Syndrome of Menopause (GSM)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Hormone Therapy (HT) topic
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: All formats of learning modules
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Self-administered learning modules
Number of subjects: 33
Study: 31567365

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propofol and Sevoflurane
Number of subjects: 0
Study: 29167052

Group type: EXPERIMENTAL
Intervention: Exposure-based cognitive behavior therapy (CBT) for SHA, 12 weeks
Number of subjects: 132

Group type: COMPARATOR
Intervention: No treatment control condition
Number of subjects: 132
Study: 25749132

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (iCBT) program, 6-week duration, 6 lessons using a Manga story
Number of subjects: 762

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 762
Study: 23727057

Group type: EXPERIMENTAL
Intervention: Microdose of (14)C‐tolbutamide (100 μg)
Number of subjects: 0
Study: 21367381

Group type: EXPERIMENTAL
Intervention: Single-Incision Laparoscopic Cholecystectomy (SILC)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard Laparoscopic Cholecystectomy (4PLC)
Number of subjects: 83
Study: 19222929

Group type: EXPERIMENTAL
Intervention: 4 weeks of antimicrobial therapy (2 weeks intravenous ceftriaxone and 2 weeks oral ciprofloxacin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chloramphenicol or ceftriaxone treatment (duration not specified)
Number of subjects: 0
Study: 16554853

Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 12742869

Group type: EXPERIMENTAL
Intervention: Trauma-focused group psychotherapy
Number of subjects: 360

Group type: COMPARATOR
Intervention: Present-centered comparison treatment
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Trauma-focused group therapy (adequate dose)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 360
Study: 11196228

Group type: EXPERIMENTAL
Intervention: Mandibular advancement device
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (homologous control)
Number of subjects: 21
Study: 8866262

Group type: EXPERIMENTAL
Intervention: Conventional glass‐ionomer liner under amalgam restorations
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Light‐cured glass‐ionomer liner placed 0.3 mm from the cavosurface margin under composite resin restoration
Number of subjects: 70

Group type: COMPARATOR
Intervention: Two layers of copal varnish and amalgam
Number of subjects: 70

Group type: COMPARATOR
Intervention: Light‐cured glass‐ionomer and amalgam
Number of subjects: 70

Group type: COMPARATOR
Intervention: Bonding agent and light‐cured composite resin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional glass‐ionomer, bonding agent and light‐cured composite resin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Light‐cured glass‐ionomer, extended 0.3 mm short of the enamel margin, bonding agent and light‐cured composite resin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Light‐cured glass‐ionomer, extended 1 mm short of the enamel margin, bonding agent and light‐cured composite resin
Number of subjects: 70
Study: 1626042

Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 12
Study: 6389645

Group type: EXPERIMENTAL
Intervention: Exercise training for 1 year
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 107
Study: 31335642

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (20 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 29764487

Group type: EXPERIMENTAL
Intervention: TPF (taxane, cisplatin, and 5-fluorouracil)
Number of subjects: 1879
Study: 26930607

Group type: EXPERIMENTAL
Intervention: GSK1070806 0.25 mg/kg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: GSK1070806 5 mg/kg
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 24456510

Group type: EXPERIMENTAL
Intervention: Weekly monetary incentives for fitness-center attendance during fall semester
Number of subjects: 117

Group type: COMPARATOR
Intervention: Discontinued-incentive condition (no incentives during spring semester)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Continued-incentive condition (variable-interval schedule during spring semester)
Number of subjects: 117
Study: 22198821

Group type: EXPERIMENTAL
Intervention: Aloe vera leaf gel (300 mg capsule every 12 hours for 2 months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 20954664

Group type: EXPERIMENTAL
Intervention: Viscoseal (hyaluronic acid) injection
Number of subjects: 56

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 56
Study: 18203570

Group type: EXPERIMENTAL
Intervention: INSIGHT therapy
Number of subjects: 0
Study: 16355440

Group type: EXPERIMENTAL
Intervention: Oral administration of rhubarb extract (50 mg.kg(‐1))
Number of subjects: 8

Group type: COMPARATOR
Intervention: Retention enema administration of rhubarb extract (50 mg.kg(‐1))
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both oral and retention enema administration of rhubarb extract
Number of subjects: 8
Study: 11867397

Group type: EXPERIMENTAL
Intervention: Hyperbaric ropivacaine (25 mg in 8.3% glucose)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Plain ropivacaine (25 mg)
Number of subjects: 40
Study: 9892302

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 422

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 422
Study: 7474676

Group type: EXPERIMENTAL
Intervention: Naloxone 0.1 mg/kg i.v. bolus, followed by 0.1 mg/kg/hr
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Head-out water immersion (HOI)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: HOI during concomitant naloxone administration
Number of subjects: 6
Study: 2180527

Group type: EXPERIMENTAL
Intervention: Hospital admission
Number of subjects: 77

Group type: COMPARATOR
Intervention: Discharge home
Number of subjects: 77
Study: 44770

Group type: EXPERIMENTAL
Intervention: Bunitrolol (Group A)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Hyoscin-N-butyl-bromide and diazepam (Group B)
Number of subjects: 3

Group type: COMPARATOR
Intervention: No premedication (Group C)
Number of subjects: 3
Study: 28385954

Group type: EXPERIMENTAL
Intervention: My Healthy Choices (intervention programme)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention-matched control
Number of subjects: 0
Study: 28137634

Group type: EXPERIMENTAL
Intervention: Metoclopramide administration in patients with NLR greater than 2 (group II)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Metoclopramide administration in patients with NLR less than 2 (group I)
Number of subjects: 64
Study: 26506581

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) + Parent Training (PT)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Placebo + Parent Training (PT)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 24026159

Group type: EXPERIMENTAL
Intervention: Chiropractic therapy
Number of subjects: 183

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 183
Study: 20697967

Group type: EXPERIMENTAL
Intervention: Reduced workload (average census of 3.5 patients)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Typical workload (average census of 6.6 patients)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Reduced workload
Number of subjects: 61

Group type: COMPARATOR
Intervention: Typical workload
Number of subjects: 61
Study: 19478228

Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator
Number of subjects: 0
Study: 17079090

Group type: EXPERIMENTAL
Intervention: Public service announcements with pictures and textual arguments
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Public service announcements with pictures only
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Public service announcements with textual arguments only
Number of subjects: 159

Group type: COMPARATOR
Intervention: Public service announcements without pictures and textual arguments
Number of subjects: 159
Study: 15366789

Group type: EXPERIMENTAL
Intervention: Eprosartan 600 mg
Number of subjects: 86

Group type: COMPARATOR
Intervention: Losartan 100 mg
Number of subjects: 86
Study: 11710710

Group type: EXPERIMENTAL
Intervention: diacerein (50 mg twice a day)
Number of subjects: 507

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 507
Study: 9008377

Group type: EXPERIMENTAL
Intervention: Previous income level (nonsalient condition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Income and work experience (salient condition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined data from Study 1 and Study 2 (nonsalient condition)
Number of subjects: 0
Study: 8331204

Group type: EXPERIMENTAL
Intervention: Vigabatrin single oral doses (0.5 to 4.0 g)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Vigabatrin multiple oral doses (0.5 to 2.0 g every 12 hours)
Number of subjects: 24
Study: 3579007

Group type: EXPERIMENTAL
Intervention: Constant-load exercise tests above lactate threshold (LT)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Constant-load exercise tests below lactate threshold (LT)
Number of subjects: 6
Study: 29751001

Group type: EXPERIMENTAL
Intervention: Ixekizumab (160 mg starting dose followed by 80 mg every 2 weeks, then 80 mg every 4 weeks during extension)
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Ixekizumab (in TE-ADA-positive patients)
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Ixekizumab (in TE-ADA-high titer group)
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Ixekizumab (overall efficacy)
Number of subjects: 373
Study: 27621193

Group type: EXPERIMENTAL
Intervention: High PA diet (HPA)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low PA and high OA diet (HOA)
Number of subjects: 12
Study: 24122840

Group type: EXPERIMENTAL
Intervention: Atenolol monotherapy
Number of subjects: 456

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) monotherapy
Number of subjects: 456

Group type: COMPARATOR
Intervention: Combination therapy with atenolol and HCTZ
Number of subjects: 456
Study: 23034421

Group type: EXPERIMENTAL
Intervention: At-home tray technique (5.0% H2O2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Over-the-counter strip technique (5.3% H2O2)
Number of subjects: 30
Study: 20879647

Group type: EXPERIMENTAL
Intervention: Alternative surgical flap (ASF)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard reverse L-flap (RLF)
Number of subjects: 33
Study: 18194383

Group type: EXPERIMENTAL
Intervention: Delayed clamping of the umbilical cord (1 minute after delivery)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Immediate clamping of the umbilical cord
Number of subjects: 105
Study: 16394615

Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Intracoronary thrombolysis
Number of subjects: 76
Study: 12093440

Group type: EXPERIMENTAL
Intervention: Enteral fiber‐containing nutrition with living Lactobacillus (group B)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Enteral fiber‐containing nutrition with heat‐killed Lactobacillus (group C)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Parenteral nutrition or fiber‐free enteral nutrition (group A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Living Lactobacillus vs heat‐killed Lactobacillus
Number of subjects: 90
Study: 10622071

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 250 mg b.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefixime 200 mg b.d.
Number of subjects: 0
Study: 8787257

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthetic (propofol for induction followed by propofol infusion)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Combined intravenous‐inhalational anaesthetic (propofol with isoflurane in oxygen‐enriched air)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Balanced inhalational anaesthetic (thiopentone for induction and oxygen in nitrous oxide with isoflurane for maintenance)
Number of subjects: 235
Study: 2025840

Group type: EXPERIMENTAL
Intervention: Craniospinal irradiation plus a local boost (CS‐XRT)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Local irradiation only (L‐XRT)
Number of subjects: 17

Group type: COMPARATOR
Intervention: No irradiation (NRT)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Age < 4 years at diagnosis
Number of subjects: 17

Group type: COMPARATOR
Intervention: Age > 4 years at diagnosis
Number of subjects: 17

Group type: COMPARATOR
Intervention: Local radiation doses over 4500 cGy
Number of subjects: 17

Group type: COMPARATOR
Intervention: Local radiation doses less than 4500 cGy
Number of subjects: 17
Study: 7282308

Group type: COMPARATOR
Intervention: BFTZ + P
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: E/N
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: BFTZ + E/N
Number of subjects: 97
Study: 6465150

Group type: EXPERIMENTAL
Intervention: Automated bedside dispensing machine (McLaughlin Dispensing System)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Decentralized unit dose system (control)
Number of subjects: 32
Study: 30032545

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 74
Study: 27680969

Group type: EXPERIMENTAL
Intervention: Diode laser (980 nm, 100 mW, 5.6 J/cm2, applied on days 0, 7, 14, 21, and 28 during canine retraction)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (laser pseudo-application)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Diode laser (980 nm)
Number of subjects: 11
Study: 24813374

Group type: EXPERIMENTAL
Intervention: Long-acting dexmethylphenidate (D-MPH) at doses of 10-20 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts (MAS) at doses of 10-20 mg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Long-acting dexmethylphenidate (D-MPH) and Mixed amphetamine salts (MAS)
Number of subjects: 56
Study: 23123106

Group type: EXPERIMENTAL
Intervention: AH-adjuvanted PcpA (25 μg)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: AH-adjuvanted PhtD-PcpA (10, 25, or 50 μg each)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Unadjuvanted PhtD-PcpA (25 μg each)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: AH-adjuvanted vaccines
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 20124925

Group type: EXPERIMENTAL
Intervention: Distribution templates of fiducial points
Number of subjects: 85

Group type: COMPARATOR
Intervention: Real fiducial points
Number of subjects: 85
Study: 19195328

Group type: EXPERIMENTAL
Intervention: pegylated interferon‐alpha2b for 8 weeks
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: lamivudine plus pegylated interferon‐alpha2b combination therapy for 24 weeks
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: lamivudine monotherapy for 28 weeks
Number of subjects: 47
Study: 15787659

Group type: EXPERIMENTAL
Intervention: Insulin lispro mixture plus metformin
Number of subjects: 97

Group type: COMPARATOR
Intervention: Glargine plus metformin
Number of subjects: 97
Study: 12453070

Group type: EXPERIMENTAL
Intervention: 0.2 g/kg IVIG
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 0.4 g/kg IVIG
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 10404574

Group type: EXPERIMENTAL
Intervention: Paraspinal muscle fatigue (induced by upper trunk repetitive extensions against resistance until exhaustion)
Number of subjects: 106

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 106
Study: 7560627

Group type: EXPERIMENTAL
Intervention: Low intensity exercise training (40% of peak oxygen uptake) three times/week for 8 weeks
Number of subjects: 27
Study: 2248072

Group type: EXPERIMENTAL
Intervention: Moclobemide (300 to 328 mg in first study; 294-408 mg in second study)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Amitriptyline (75 to 96 mg in first study; 95-129 mg in second study)
Number of subjects: 44
Study: 7364977

Group type: EXPERIMENTAL
Intervention: Corticosteroid antimicrobial cream with fluocinonide 0.05%
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Corticosteroid antimicrobial cream with triamcinolone 0.1%
Number of subjects: 88

Group type: COMPARATOR
Intervention: Cream containing only antimicrobial agents
Number of subjects: 88
Study: 31835476

Group type: EXPERIMENTAL
Intervention: Fibre-enriched orange juice (1.4 g/100 mL of citrus fibre)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (regular orange juice without added fibre)
Number of subjects: 10
Study: 29856685

Group type: EXPERIMENTAL
Intervention: ibrutinib plus rituximab
Number of subjects: 150

Group type: COMPARATOR
Intervention: placebo plus rituximab
Number of subjects: 150
Study: 26163858

Group type: EXPERIMENTAL
Intervention: Patient education with exercise therapy
Number of subjects: 121

Group type: COMPARATOR
Intervention: Patient education without exercise therapy
Number of subjects: 121
Study: 24170391

Group type: EXPERIMENTAL
Intervention: Novel dog
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Human friend
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48